Cancer remains the second leading cause of death in the United States and it is estimated that over 500,000 individuals will die in the United States alone during 188. Historically, natural products or compounds modeled on them have found significant utility in the treatment of cancer and a number of marine-derived compounds are currently under clinical investigation. Advances in our understanding of neoplastic progression have provided new targets for intervention in cancer and may provide novel therapies with reduced side effects. In this proposal we seek to substantiate our hypothesis that marine natural products (MNPs) can be discovered which interact at these defined molecular targets and that these compounds, or compounds modeled upon them, will be useful in the treatment of cancer. The project will be carried out in collaboration with the Novartis Oncology Research group (NIBR), the Crews MNP group at UC Santa Cruz (UCSC) and the Gerwick group at Oregon State University (OSU). HBOI brings to the existing NPDDG a complementary set of extracts and expertise.
The specific aims of the HBOI project are: 1. To provide a diverse and complementary library of extracts and enriched fractions to Project 1 (Novartis) for assay. These materials will be derived from marine invertebrates and fermentation of invertebrate- associated marine microorganisms. Focus will be on organisms derived from depths that those to typically accessible by acute (>200 feet of sea water). 2. To define whether fractionation and enrichment of the extracts through simple chromatographic procedures enhances the success rate for discovery of bioactive compounds by decreasing nuisance compounds, salts and complexity while increasing the concentration of the secondary metabolites assayed in the HTSs. 3. To rapidly deconvolute active extracts and fractions and define the structures of the active component(s). 4. To provide sufficient compound to the NIBR to allow for secondary biological testing and follow up.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19CA052955-11
Application #
6402470
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1990-09-01
Project End
2005-04-30
Budget Start
Budget End
Support Year
11
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of California Santa Cruz
Department
Type
DUNS #
City
Santa Cruz
State
CA
Country
United States
Zip Code
95064
Sabry, Omar M; Goeger, Douglas E; Gerwick, William H (2017) Biologically active new metabolites from a Florida collection of Moorea producens. Nat Prod Res 31:555-561
Sabry, Omar M M; Goeger, Douglas E; Valeriote, Frederick A et al. (2017) Cytotoxic halogenated monoterpenes from Plocamium cartilagineum. Nat Prod Res 31:261-267
Sabry, Omar M M; Goeger, Douglas E; Gerwick, William H (2017) Bioactive new metabolites from the green alga Udotea orientalis growing on the Gorgonian coral Pseudopterogorgia rigida. Nat Prod Res 31:1245-1250
Guzmán, Esther A; Maers, Kelly; Roberts, Jill et al. (2015) The marine natural product microsclerodermin A is a novel inhibitor of the nuclear factor kappa B and induces apoptosis in pancreatic cancer cells. Invest New Drugs 33:86-94
Tan, Lik Tong; Okino, Tatsufumi; Gerwick, William H (2013) Bouillonamide: a mixed polyketide-peptide cytotoxin from the marine cyanobacterium Moorea bouillonii. Mar Drugs 11:3015-24
Wu, Q X; Jin, X J; Draskovic, M et al. (2012) Unraveling the Numerous Biosynthetic Products of the Marine Sediment-Derived Fungus, Aspergillus insulicola. Phytochem Lett 5:114-117
Malloy, Karla L; Choi, Hyukjae; Fiorilla, Catherine et al. (2012) Hoiamide D, a marine cyanobacteria-derived inhibitor of p53/MDM2 interaction. Bioorg Med Chem Lett 22:683-8
Luo, Xiao-Hong; Wang, Xiao-Zheng; Jiang, Hai-Long et al. (2012) The biosynthetic products of Chinese insect medicine, Aspongopus chinensis. Fitoterapia 83:754-8
Valeriote, Frederick A; Tenney, Karen; Media, Joseph et al. (2012) Discovery and development of anticancer agents from marine sponges: perspectives based on a chemistry-experimental therapeutics collaborative program. J Exp Ther Oncol 10:119-34
Jiang, Hai-Long; Luo, Xiao-Hong; Wang, Xiao-Zheng et al. (2012) New isocoumarins and alkaloid from Chinese insect medicine, Eupolyphaga sinensis Walker. Fitoterapia 83:1275-80

Showing the most recent 10 out of 47 publications